Abstract 102P
Background
In TOPAZ-1 (NCT03875235), durvalumab (D) + gemcitabine and cisplatin (GC) improved overall survival (OS) vs placebo (PBO) + GC in participants with advanced biliary tract cancer (aBTC; primary analysis: hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.66–0.97, p=0.021 [significance threshold p=0.03]) and after a further 6.5 months of follow-up (HR 0.76, 95% CI 0.64–0.91). This exploratory analysis assessed baseline clinical factors for potential prognostic (associated with OS) or predictive (of OS benefit with D + GC) value in TOPAZ-1.
Methods
Potentially prognostic factors were evaluated using Cox proportional hazards models with treatment and each factor. An exploratory adjusted HR for D + GC vs PBO + GC was estimated with a model adjusting for prognostic factors identified by stepwise selection. Unstratified Cox proportional hazards models and interaction tests were performed to assess potential predictive factors. Data cut-off was 25 February 2022.
Results
Potentially prognostic clinical factors are shown (Table). The HR for D + GC vs PBO + GC, adjusted for disease status, primary tumour location, sex, PD-L1, neutrophil to lymphocyte ratio (NLR), cancer antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), liver metastasis, liver involvement (locally advanced or metastatic site in liver/gallbladder), body weight, LDH, albumin and total bilirubin, was 0.70 (95% CI 0.59–0.84). OS HRs for D + GC vs PBO + GC were <1 across assessed clinical (Table) and laboratory factors; no predictive factors for D + GC were found. Table: 102P
Predictive | Prognostic | ||||
Factor | Subgroup | HR (95% CI), D + GC v PBO + GC | Interaction p | HR (95% CI), top v bottom subgroup | p |
Disease status | IU | .79 (.65–.95) | .93 | 2.14 (1.69–2.76) | <.01 |
R | .76 (.49–1.20) | ||||
ECOG PS | 0 | .87 (.68–1.12) | .14 | 1.29 (1.09–1.53) | <.01 |
1 | .70 (.55–.89) | ||||
Disease classification | LA | .54 (.32–.88) | .13 | 1.35 (1.05–1.76) | .02 |
M | .80 (.67–.97) | ||||
NLR | <3 | .75 (.56–1.01) | .83 | 2.14 (1.79–2.58) | <.01 |
≥3 | .76 (.61–.94) | ||||
CA19-9 | <500 U/mL | .72 (.57–.92) | .53 | 2.08 (1.73–2.50) | <.01 |
≥500 U/mL | .82 (.62–1.08) | ||||
CEA | <5 ng/mL | .75 (.58–.97) | .75 | 1.78 (1.49–2.14) | <.01 |
≥5 ng/mL | .81 (.63–1.05) | ||||
Liver metastasis | Y | .83 (.66–1.06) | .32 | 1.37 (1.56–1.63) | <.01 |
N | .69 (.54–.88) | ||||
Liver involvement | Y | .76 (.63–.91) | .76 | 1.67 (1.32–2.14) | <.01 |
N | .77 (.49–1.20) |
IU, initially unresectable; LA, locally advanced; M, metastatic; R, recurrent
Conclusions
Benefit with D + GC was consistent across assessed factors and stable after adjusting for potentially prognostic factors, supporting D + GC as first-line treatment for aBTC.
Clinical trial identification
NCT03875235.
Editorial acknowledgement
Medical writing support, under the direction of the authors, was provided by Elaine Groat, PhD, of CMC Connect, a division of IPG Health Medical Communications, funded by AstraZeneca, in accordance with Good Publication Practice (GPP 2022) guidelines.
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
A.R. He: Financial Interests, Personal, Research Grant: AstraZeneca, Genentech, Merck; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Eisai, BMS. M. Bouattour: Financial Interests, Personal, Advisory Board: MSD, BMS, Sirtex Medical, Ipsen, AbbVie, AstraZeneca, Servier, Taiho; Financial Interests, Personal, Invited Speaker: Roche; Non-Financial Interests, Principal Investigator: MSD, BMS, Sirtex Medical, AstraZeneca. V.G. Gupta: Financial Interests, Personal, Stocks/Shares: Zydus Life, RPG Life. L. Evesque: Financial Interests, Personal, Advisory Board: Servier, Amgen, MSD, Merck. D.B. Zhen: Financial Interests, Personal, Advisory Board: QED Therapeutics, Ipsen; Financial Interests, Other, Local PI and Coordinating PI: Merck; Financial Interests, Invited Speaker: TME Pharma, AstraZeneca, Bristol Meyers Squibb, Legend Biotech, Genentech, Cornerstone Pharmaceuticals, Eli Lilly, Seagen, NeoTx Therapeutics, Daiichi Sankyo; Non-Financial Interests, Leadership Role, Binaytara Foundation: Gastrointestinal Oncology Education Chair; Non-Financial Interests, Other, Panel Member of NCCN Neuroendocrine and Adrenal Tumor Guidelines: National Comprehensive Cancer Network. J.O. Park: Financial Interests, Personal, Advisory Board: MedPacto, BMS (Celgene), Servier, MediRama, Adicet Bio, AstraZeneca, Merck Sereno; Financial Interests, Personal, Other, Travel support for a poster presentation at ASCO GI 2023: Minneamrita Therapeutics LLC; Financial Interests, Personal, Research Grant, Clinical research grant: MedPacto, Servier, BMS (Celgene); Financial Interests, Personal, Research Grant: Eutilex, ABL Bio. A. Sookprasert: Financial Interests, Personal, Invited Speaker: AstraZeneca, Bristol, Easai, Merck, Roche, Jansen, Pfizer, Novartis. A. Salvatierra: Non-Financial Interests, Personal and Institutional, Principal Investigator: Fundacion Ars Medica. G.M. Vaccaro: Financial Interests, Personal, Speaker’s Bureau: Incyte; Financial Interests, Personal, Advisory Board: AstraZeneca, GSK; Financial Interests, Personal, Advisory Role: Servier. S.A. Ostoich: Non-Financial Interests, Personal, Principal Investigator: Hospital Provincial del Centenario. T. Satoh: Financial Interests, Personal, Invited Speaker, invited speaker and advisory: Ono Pharmaceutical, Daiichi-Sankyo; Financial Interests, Personal, Invited Speaker, Invited speaer and adovisory: Bristol-Myers; Financial Interests, Personal, Invited Speaker, Invited speaker and advisory: Elli-Lilly, Yakult-HOnsha; Financial Interests, Personal, Invited Speaker: Chugai Pharmazeutical, Merck-Biopharm, Takeda, Taiho; Financial Interests, Personal, Advisory Board: Takara-Bio; Financial Interests, Institutional, Invited Speaker: Merck-Biopharm; Financial Interests, Institutional, Invited Speaker, Research Grant and Endosed Department: Ono Pharmaceutical, Chugai Pharmaceutical, Yakult Honsha; Financial Interests, Institutional, Invited Speaker, Research Grant: Bristol-Myers, Elli-Lilly, Daiichi Sankyo, Parexell, Giliad, Taiho, Hutch-Med. M. Żotkiewicz: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. N. Rokutanda: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. H. Kim: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. D. Oh: Financial Interests, Personal, Advisory Board: AstraZeneca, Novartis, Genentech/Roche, Merck Serono , Bayer, Taiho, ASLAN, Halozyme, Zymeworks, BMS/Celgene, BeiGene, Basilea, Turning Point, Yuhan, Arcus Biosciences, IQVIA, MSD; Financial Interests, Institutional, Research Grant: AstraZeneca, Novartis, Array, Eli Lilly, Servier, BeiGene, MSD, Handok. All other authors have declared no conflicts of interest.
Resources from the same session
107P - Comprehensive genomic profiling of “The German-registry of incidental gallbladder carcinoma” cases
Presenter: Nihat Bugra Agaoglu
Session: Poster session 17
108P - FGFR2 fusions and their impact on efficacy of standard chemotherapy in patients with biliary tract cancer
Presenter: Binbin Zheng-Lin
Session: Poster session 17
109P - DNA damage repair pathways in biliary tract cancer: A new target for precision medicine?
Presenter: Ilektra Mavroeidi
Session: Poster session 17
110P - Detection of HER2 overexpression in biliary tract cancers: Comparison of AmoyDx® HER-2 (29D8) assay with ventana PATHWAY anti-HER-2/neu (4B5) assay
Presenter: Hui Dong
Session: Poster session 17
111P - The concordance between circulating tumor DNA and tissue genomic profiling in patients with advanced biliary tract cancer
Presenter: Seonjeong Woo
Session: Poster session 17
112P - Clinical, genomic and transcriptomic characteristics of young-onset biliary tract cancers
Presenter: Thomas Pudlarz
Session: Poster session 17
113P - Molecular profiling of biliary tract cancers in patients of African and European ancestries
Presenter: Zishuo Hu
Session: Poster session 17
114P - Prospective longitudinal tumor-informed ctDNA in resectable biliary tract cancers
Presenter: Gentry King
Session: Poster session 17
115P - Inhibition of KLF5 reduces tumor growth and sensitizes to chemotherapy-induced cell death in experimental models of cholangiocarcinoma
Presenter: Ana Landa Magdalena
Session: Poster session 17
116P - Circulating tumour DNA- based minimal residual disease detection for biliary tract cancer
Presenter: Zhishuai Li
Session: Poster session 17